Ribociclib Succinate and Letrozole
Kisqali Femara Co-Pack combines two drugs into one package: ribociclib succinate (Kisqali) and letrozole (Femara). Ribociclib succinate is a targeted therapy drug that blocks proteins called CDK4 and CDK6 that cancer cells need to grow. Letrozole is a hormone therapy and targeted therapy drug that blocks a protein called aromatase, which the body uses to make estrogen. Blocking aromatase lowers estrogen levels, which helps slow or stop the growth of breast cancer cells that need estrogen to grow.
FDA label information for this drug is available at DailyMed.
Use in Cancer
The ribociclib succinate and letrozole co-pack is approved to treat:
- breast cancer that is hormone receptor positive (HR+) and HER2 negative (HER2-). It is used:
- for stage II or stage III early breast cancer that is at high risk of coming back
- as the first hormone-based therapy for cancer that has spread
Ribociclib succinate and letrozole are also available separately as ribociclib succinate and letrozole. For more information that may apply to these drugs, see the Drug Information Summaries for Ribociclib Succinate and Letrozole.
More About Ribociclib Succinate and Letrozole
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer
Hormone Therapy to Treat Breast Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Ribociclib Succinate/letrozole - Check for trials from NCI's list of cancer clinical trials now accepting patients.